Central line-associated bloodstream infection (CLABSI), caused by pathogens entering the bloodstream through central venous catheters, remains a significant threat to patients in intensive care units (ICU). In response to the evolving clinical evidence and antimicrobial resistance trends, the Chinese Society of Critical Care Medicine (CSCCM) has released updated clinical guidelines for CLABSI covering its diagnosis, prevention, and treatment. Based on rigorous research and expert recommendations, the guidelines aim to standardize catheter management—supporting safer ICU care.

New antibody–drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting the gp120 on the viral envelope via a two-step mechanism, the ADCs effectively block viral entry—offering seven times better efficacy than existing approaches. Overall, the findings point towards a promising new direction for HIV treatment—targeting two viral sites with a single molecule.